239 related articles for article (PubMed ID: 16227099)
41. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
42. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
43. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
44. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
Srinivas U; Pillai LS; Kumar R; Pati HP; Saxena R
Am J Hematol; 2007 Apr; 82(4):314-6. PubMed ID: 17013815
[TBL] [Abstract][Full Text] [Related]
45. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery.
Masood I; Negi A; Dua HS
J Cataract Refract Surg; 2005 Dec; 31(12):2427-8. PubMed ID: 16473243
[TBL] [Abstract][Full Text] [Related]
46. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
47. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.
Scheinfeld N
J Drugs Dermatol; 2006 Mar; 5(3):228-31. PubMed ID: 16573254
[TBL] [Abstract][Full Text] [Related]
48. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
49. Hypolipemiant besides antileukemic effect of imatinib mesylate.
Gologan R; Constantinescu G; Georgescu D; Ostroveanu D; Vasilache D; Dobrea C; Iancu D; Popov V
Leuk Res; 2009 Sep; 33(9):1285-7. PubMed ID: 19327828
[TBL] [Abstract][Full Text] [Related]
50. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
51. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
52. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
[TBL] [Abstract][Full Text] [Related]
53. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
54. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Bee PC; Gan GG; Teh A; Haris AR
Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
[TBL] [Abstract][Full Text] [Related]
55. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
Breccia M; Cannella L; Montefusco E; Frustaci A; Pacilli M; Alimena G
Leuk Res; 2008 Mar; 32(3):519-20. PubMed ID: 17804066
[No Abstract] [Full Text] [Related]
56. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
[TBL] [Abstract][Full Text] [Related]
57. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Hatfield A; Owen S; Pilot PR
Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
[No Abstract] [Full Text] [Related]
58. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
[No Abstract] [Full Text] [Related]
59. Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
Pasmatzi E; Monastirli A; Matsouka P; Tsambaos D
Acta Derm Venereol; 2003; 83(5):391-2. PubMed ID: 14609118
[No Abstract] [Full Text] [Related]
60. Follicular mucinosis associated with imatinib (STI571).
Yanagi T; Sawamura D; Shimizu H
Br J Dermatol; 2004 Dec; 151(6):1276-8. PubMed ID: 15606531
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
